Delta Lloyd Asset Management N.V. bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,088 shares of the medical device company’s stock, valued at approximately $738,000.
Several other hedge funds have also modified their holdings of DXCM. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of DexCom in the 1st quarter valued at $136,000. IFP Advisors Inc grew its holdings in DexCom by 9.3% during the 1st quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after purchasing an additional 159 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in DexCom during the 1st quarter valued at $164,000. Independent Portfolio Consultants Inc. grew its holdings in DexCom by 0.4% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after purchasing an additional 9 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in DexCom by 475.0% during the 1st quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after purchasing an additional 1,900 shares in the last quarter.
DexCom, Inc. (NASDAQ:DXCM) traded down 0.53% during mid-day trading on Friday, reaching $71.97. 234,042 shares of the company’s stock were exchanged. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $94.79. The company’s market cap is $6.23 billion. The stock has a 50-day moving average price of $72.36 and a 200 day moving average price of $74.17.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period last year, the business earned ($0.24) EPS. Equities analysts predict that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.
Several brokerages have weighed in on DXCM. Barclays PLC began coverage on shares of DexCom in a report on Friday. They set an “equal weight” rating and a $76.00 price objective for the company. Piper Jaffray Companies reissued a “buy” rating and set a $78.00 price objective on shares of DexCom in a report on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $92.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Wednesday, August 2nd. BidaskClub lowered shares of DexCom from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $90.00 price target (down from $105.00) on shares of DexCom in a report on Tuesday, August 8th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $86.87.
ILLEGAL ACTIVITY NOTICE: “10,088 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Delta Lloyd Asset Management N.V.” was reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://baseballnewssource.com/markets/delta-lloyd-asset-management-n-v-takes-position-in-dexcom-inc-dxcm/1602478.html.
In related news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total value of $113,375.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10. Following the completion of the transaction, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at $5,448,447.70. The disclosure for this sale can be found here. Insiders have sold a total of 26,223 shares of company stock valued at $1,881,249 over the last ninety days. Company insiders own 1.70% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.